arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

PROKIDNEY CORP.

PROK

$1.64 ▼ -0.01 (-0.61%) at close

7 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Neutral

auto_awesome

Analytical Summary

PROKIDNEY CORP. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —

Dividend Yield —

Revenue Growth 1075.0%

Op. Margin —

ROIC 16.4% ↘

FCF / Share None

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$893.00K

↑ +1075.0% —

Net Income Profit after all expenses

$-68.99M

↓ -12.7% —

Health Breakdown

Returns

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	1075.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+13338%)	—	—	—	—	—	—
Net Income Growth YoY (%)	-12.7% Weak ↑ Weak Improving Year-over-year change in net income	-72.5% Weak ↓ Weak Declining Year-over-year change in net income	76.1% Excellent ↑ Excellent Improving Year-over-year change in net income	-168.6% Weak Weak Year-over-year change in net income	-106.2% Weak Weak Year-over-year change in net income	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	-0.3% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.4% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-4.6% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.6% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.9% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	1.96x Excellent ↓ Excellent Declining Free cash flow relative to reported net income Optimal: > 1x	2.55x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	3.50x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.53x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.15x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	16.4% Excellent → Excellent Stable Return earned on debt + equity capital invested Optimal: > 10%	18.4% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	14.4% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	14.0% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	-204.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-271.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-49.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-41.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-36.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-29.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-136.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	6.8% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-55%)	6.1% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-59%)	3.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-79%)	13.5% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-10%)	-204.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1466%)	-271.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1908%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	-41251.75x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-20408.44x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-12626.83x Weak Weak Operating income divided by interest expense Optimal: > 5x	-711.66x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-108.54M	$-99.12M	$-60.65M	$-490.25M	$-20.56M	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	—	—	—	$-0.23	—	—	—
Free Cash Flow per Share (USD)	—	—	—	$-1.28	—	—	—
Book Value per Share (USD)	—	—	—	$-17.82	—	—	—
Tangible Book Value per Share (USD)	—	—	—	$-17.82	—	—	—
Basic Weighted Avg Shares (shares)	—	—	—	61.54M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$249.94M	$359.67M	$349.11M	$493.85M	$14.96M	—	—
Total Equity (USD)	$-1.01B	$-994.95M	$-1.10B	$-1.10B	$26.92M	$9.86M	$15.88M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$893.00K	$76.00K	$0.00	—	—	—	—
Depreciation Expense (USD)	$6.58M	$5.43M	$3.85M	$3.04M	$1.98M	$964.00K	—
Net Income, GAAP (USD)	$-68.99M	$-61.19M	$-35.47M	$-148.13M	$-55.15M	$-26.75M	—
Operating Cash Flow (USD)	$-120.12M	$-126.35M	$-90.07M	$-77.09M	$-50.30M	$-25.18M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 23 quarters

PROKIDNEY CORP.

Analytical Summary

7-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare PROK with peers